Antibodies are being developed to target other cancer-specific overexpressed intracellular proteins, such as human telomerase reverse transcriptase (hTERT), MUC1, NY-ESO1, TCR gamma alternate reading frame protein (TARP), p53, WT1, and preferentially expressed antigen of melanoma (PRAME) (94), with early clinical trial results for PRAME showing promising outcomes. The gene discussed is TARP; the disease is melanoma.